肝内胆管癌患者预后的影响因素分析

doi:10.3969/j.issn.1671-7171.2023.03.003

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1339 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨肝内胆管癌(intrahepatic cholangiocarcinoma,ICC)患者预后的影响因素。【方法】收集福建医科大学孟超肝胆医院收治的64例ICC患者的临床资料,采用单因素、多因素COX回归模型分析ICC患者预后的影响因素,采用Kaplan-Meier生存曲线分析不同因素对ICC患者预后的影响。【结果】糖链抗原19-9(CA19-9)升高、肝外转移及大胆管型ICC是影响ICC患者预后的独立危险因素;CA19-9升高、肝外转移及大胆管型ICC患者预后较差(均P<0.05)。【结论】CA19-9升高、发生肝外转移以及大胆管型ICC可显著影响ICC患者预后。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	黄丽云
	陈怡
	吕旭江
	王斌

关键词 ：胆管, 肝内, 胆管肿瘤, 预后, 危险因素

Abstract：【Objective】 To investigate the independent risk factors affecting the surgical prognosis of patients with intrahepatic cholangiocarcinoma (ICC). 【Methods】 The clinicopathological data and prognostic information of 64 ICC patients were collected. Univariate and multivariate COX proportional hazards regression models were used to analyze the independent risk factors affecting the prognosis,and Kaplan-Meier survival curves were drawn to compare the effects of different factors on the prognosis of patients. 【Results】 Elevated carbohydrate antigen 19-9(CA19-9),extrahepatic metastasis and large duct type of ICC were independent risk factors for the prognosis of patients with ICC. The prognosis of patients with elevated CA19-9,extrahepatic metastasis and large duct ICC was poor,and the differences were statistically significant (all P<0.05). 【Conclusion】 Elevated CA19-9,extrahepatic metastasis and ICC with large duct type are independent risk factors for the prognosis of patients with ICC.

Key words： Bile Ducts,Intrahepatic Bile Duct Neoplasms Prognosis Risk Factors

收稿日期: 2022-03-14

中图分类号:

R735.8

基金资助:福建省福州市卫生健康中青年科学研究项目(2021-S-wq27);福建医科大学启航基金项目(2019QH1295)

通讯作者: ** E-mail:doctorwang2001@163.com

引用本文:

黄丽云, 陈怡, 吕旭江, 王斌. 肝内胆管癌患者预后的影响因素分析[J]. 医学临床研究, 2023, 40(3): 328-331.
HUANG Li-yun, CHEN Yi, LYU Xu-jiang, et al. Analysis of the Influencing Factors of Surgical Prognosis in Patients with Intrahepatic Cholangiocarcinoma. JOURNAL OF CLINICAL RESEARCH, 2023, 40(3): 328-331.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2023.03.003 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2023/V40/I3/328

[1] BANALES J M.Cholangiocarcinoma 2020:the next horizon in mechanisms and management[J].Nat Rev Gastroenterol Hepatol,2020,17(9):557-588.
[2] LIN X H,LUO J C . The risk factors and prognostic factors of intrahepatic cholangiocarcinoma[J].J Chin Med Assoc,2017,80(3):121-122.
[3] 沈锋,王葵,阎振林,等.1370例肝内胆管细胞癌肝切除术的疗效及预后因素分析[J].中华消化外科杂志,2016,15(4):319-328.
[4] NAGTEGAAL I D,ODZE R D,KLIMSTRA D,et al.The 2019 WHO classification of tumours of the digestive system[J].Histopathology,2020,76(2):182-188.
[5] LOUIS C,PAPOUTSOGLOU P,COULOUARN C. Molecular classification of cholangiocarcinoma [J].Curr Opin Gastroenterol,2020,36(2):57-62.
[6] 科技部传染病防治重大专项课题“病毒性肝炎相关肝癌外科综合治疗的个体化和新策略研究”专家组. 肝内胆管癌外科治疗中国专家共识(2020版) [J].中华消化外科杂志,2021,20(1):1-15.
[7] KELLEY R,BRIDGEWATER J,GORES G,et al. Systemic therapies for intrahepatic cholangiocarcinoma[J].J Hepatol,2020,72(2):353-363.
[8] 隋鑫磊,汤恢焕,肖广发,等. 322例肝门部胆管癌的临床疗效及预后因素分析[J].中华消化外科杂志,2017,16(4):391-397.
[9] 赵莹,廖冰,陈伟,等. 术前血清CA19-9联合CA125对肝内胆管癌术后病人预后预测价值研究[J].中国实用外科杂志,2020,40(8):932-938.
[10] ASAOKA T,KOBAYASHI S,HANAKI T,et al. Clinical significance of preoperative CA19-9 and lymph node metastasis in intrahepatic cholangiocarcinoma[J].Surg Today,2020,50(10):1176-1186.
[11] KENDALL T,VERHEIJ J,GAUDIO E,et al. Anatomical,histomorphological,and molecular classification of cholangiocarcinoma [J].Liver Int,2019,39 (Suppl 1):7-18.
[12] LIAU J,TSAI J,YUAN R,et al. Morphological subclassification of intrahepatic cholangiocarcinoma:etiological,clinicopathological,and molecular features[J].Mod Pathol,2014,27(8):1163-1173.
[13] HAYASHI A,MISUMI K,SHIBAHARA J,et al. Distinct clinicopathologic and genetic features of 2 histologic subtypes of intrahepatic cholangiocarcinoma[J].Am J Surg Pathol,2016,40(8):1021-1030.
[14] MOLENAAR R,MACIEJEWSKI J,WILMINK J,et al. Wild-type and mutated IDH1/2 enzymes and therapy responses[J].Oncogene,2018,37(15):1949-1960.